Bristol Myers Squibb holds its place on Wall Street
Published on 07/06/2026 at 13:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Steven Krueger, Long-Term & Business Model desk. Reviewed on July 6, 2026 at 11:39 a.m. ET.
Bristol Myers Squibb (ISIN US0897961004) is a large US pharmaceutical company built around branded medicines in oncology, hematology, immunology and cardiovascular care. The company trades on the New York Stock Exchange, and its investor case still turns on how durable its medicine portfolio remains across a slow-moving patent cycle.
Business first
The company develops and markets prescription drugs rather than consumer health products, which makes pipeline execution and reimbursement access central to results. For US investors, that means the stock is often judged alongside other large-cap healthcare names rather than the broader market.
Portfolio breadth
Bristol Myers Squibb's product set spans established therapies and newer launches, giving it multiple revenue streams but also exposure to competition as older drugs age. That mix is typical of a mature Big Pharma profile: cash flow matters, but so does whether newer treatments can offset erosion elsewhere.
More on Bristol Myers Squibb stock
Review the company profile and investor materials for a closer look at the business mix, reporting structure and capital allocation priorities.
Representative drug
One representative product is Eliquis, a prescription blood thinner used to reduce the risk of stroke and other clot-related events in approved patients. It illustrates why Bristol Myers Squibb remains tied to both volume trends and the long runway of major marketed therapies.
Trading snapshot
The shares last traded on the New York Stock Exchange at $0.00 USD as of July 6, 2026, 11:39 a.m. ET.
Bristol Myers Squibb at a glance
- Company: Bristol Myers Squibb Company
- ISIN: US0897961004
- Ticker: BMY
- Exchange: New York Stock Exchange
- Price (as of July 6, 2026, 11:39 a.m. ET): $0.00 USD
- Sector / Industry: Health Care, Pharmaceuticals
- Next earnings date: not yet officially scheduled
This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
